Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-23 EDT 5-day change 1st Jan Change
6.430 USD +0.94% Intraday chart for Altimmune, Inc. -20.62% -42.84%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000 Growth Index CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell Microcap Growth Index CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 3000E Growth Index CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2000 Growth Index CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2500 Growth Index CI
Altimmune, Inc.(NasdaqGM:ALT) added to Russell Small Cap Comp Growth Index CI
Altimmune CFO Richard Eisenstadt Dies MT
Altimmune, Inc. Appoints Andrew Shutterly as Principal Financial Officer and Principal Accounting Officer CI
Altimmune, Inc. Appoints Andrew Shutterly as Acting Chief Financial Officer CI
Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer CI
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association?s 84th Scientific Sessions CI
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup DJ
Transcript : Altimmune, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 09:20 AM
Altimmune, Inc. Presents Data at EASL International Liver Congress?? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis CI
Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM
Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 MT
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : More Earnings -2- DJ
Altimmune Shares Decline After Guggenheim Downgrade MT
Guggenheim Downgrades Altimmune to Neutral From Buy MT
Transcript : Altimmune, Inc. - Special Call
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B MT
Transcript : Altimmune, Inc., Q4 2023 Earnings Call, Mar 27, 2024
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Chart Altimmune, Inc.
More charts
Logo Altimmune, Inc.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
Employees
59
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.430USD
Average target price
20.57USD
Spread / Average Target
+219.93%
Consensus
  1. Stock Market
  2. Equities
  3. ALT Stock
  4. News Altimmune, Inc.
  5. Insider Trends: 90-Day Insider Buying Trend at Altimmune Interrupted with Disposition of Shares